The Company’s iglucose™ mobile health system for diabetes management uses mobile technology to seamlessly communicate blood glucose readings from an individual’s data-capable glucometer to the iglucose diabetes management portal, where, with the user’s consent, glucose readings can be shared automatically with family members, caregivers and healthcare professionals via text message, email or fax.
PositiveID’s Easy Check™ non-invasive breath glucose detection device, currently under development, correlates the levels of acetone in exhaled breath to a measurement of blood glucose. The goal of Easy Check is to eliminate a patient's need to prick his or her finger multiple times per day in order to get a blood sugar reading.
The Company’s GlucoChip™ glucose-sensing implantable microchip for people with diabetes, also currently under development, uses a closed-cycle glucose sensing system in combination with a RFID microchip to continuously sense blood glucose levels from within the body using an external scanner.
World Diabetes Day was created in 1991 by the International Diabetes Federation (IDF) along with the World Health Organization (WHO) and falls on November 14 each year. World Diabetes Day poses an opportunity to spread awareness and draws attention to this rapidly growing disease worldwide.
iglucose is not cleared by the FDA for sale in the U.S. The Company submitted its 510(k) for iglucose in July 2011.
About PositiveID Corporation
PositiveID Corporation (OTCBB: PSID) develops unique medical devices and molecular diagnostic systems, focused primarily on diabetes management, rapid medical testing and airborne bio-threat detection. Its wholly-owned subsidiary, MicroFluidic Systems or MFS, is focused on the development of microfluidic systems for automated preparation of and performance of biological assays. For more information on PositiveID, please visit www.PositiveIDCorp.com.
Statements about PositiveID’s future expectations, including the likelihood that Easy Check correlates the levels of acetone in exhaled breath to a measurement of blood glucose; the likelihood that Easy Check could eliminate a patient’s need to prick his or her finger multiple times per day to get a blood sugar reading; the likelihood that GlucoChip can continuously sense blood glucose levels from within the body using an external scanner; and all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include the Company’s ability to complete the development of its diabetes management products and obtain regulatory clearance from the FDA to sell these products in the U.S., as well as certain other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on February 12, 2009, and 10-Qs filed on May 13, 2011 and August 15, 2011, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.